trial summary · NCT07691450
Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma
Phase 1 Investigation of Belinostat-Based Combinations in Relapsed/Refractory T-Cell Lymphoma
Trial record from the TrialBase DB dataset, status RECRUITING, condition Recurrent Anaplastic Large Cell Lymphoma, sponsored by City of Hope Medical Center. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This phase I trial tests the safety, side effects and best dose of azacitidine in combination with belinostat and how well the combination works in treating patients with follicular helper T cell lymphoma (TFH) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). This phase I trial also tests the safety, side effects and best dose of pralatrexate in combination with belinostat and how well the combination works in treating patients with relapsed or refractory peripheral T cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL) with large cell transformation and cytotoxic phenotype. Azacitidine stops cells from making deoxyribonucleic acid (DNA) and may kill cancer cells. It is a type of antimetabolite. Pralatrexate stops cells from using folic acid to make DNA. This may help keep cancer cells from growing and may kill them. Pralatrexate is a type of antimetabolite and a type of dihydrofolate reductase inhibitor. Belinostat blocks certain enzymes needed for cell division and may kill cancer cells. It may also prevent the growth of new blood vessels that tumors need to grow and may help make cancer cells easier to kill with other anticancer drugs. It is a type of histone deacetylase inhibitor, a type of antiangiogenesis agent, and a type of chemosensitizer. Giving azacitidine in combination with belinostat may be safe, tolerable, and/or effective in treating patients with relapsed/refractory (R/R) TFH. In additional, giving pralatrexate in combination with belinostat may be safe, tolerable, and/or …
Source record: https://clinicaltrials.gov/study/NCT07691450
Facts
| registry id | NCT07691450 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE1 |
| study type | INTERVENTIONAL |
| lead condition | Recurrent Anaplastic Large Cell Lymphoma |
| sponsor | City of Hope Medical Center |
| sponsor class | OTHER |
| enrollment | 40 |
| start date | 2027-01-03 |
| primary completion | 2029-11-24 |
| completion | 2029-11-24 |
| results posted | not reported |
Conditions
- Recurrent Anaplastic Large Cell Lymphoma
- Recurrent Enteropathy-Associated T-Cell Lymphoma
- Recurrent Follicular Helper T-Cell Lymphoma
- Recurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type
- Recurrent Follicular Helper T-Cell Lymphoma, Follicular-Type
- Recurrent Follicular Helper T-Cell Lymphoma, Not Otherwise Specified
- Recurrent Hepatosplenic T-Cell Lymphoma
- Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
- Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
- Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Recurrent Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma
- Recurrent Primary Cutaneous Gamma-Delta T-Cell Lymphoma
14 more in the dataset.
Interventions
- Azacitidine
- Belinostat
- Biospecimen Collection
- Computed Tomography
- FDG-Positron Emission Tomography
- Fludeoxyglucose F-18
- Positron Emission Tomography
- Pralatrexate
- Questionnaire Administration
Countries
- United States
Intervention types: DRUG, OTHER, PROCEDURE
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.